This was followed by “Hypoadiponectinemia in obesity and type 2 diabetes: Close association with insulin resistance and hyperinsulinemia” published in JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (Q1, IF = 5), with 2,855 citations, and “Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome” published in JOURNAL OF CLINICAL INVESTIGATION (Q1, IF = 13.3), which had 2,175 citations. Here, ADIPOQ is linked to metabolic syndrome.